source
- Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic diseaseSanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain.BioSpace · 1h ago↗ source
- FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher diseaseThe U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…